

UK SAR Projects

Project (1)

Title – Obesity related severe asthma – relationship between body mass index and symptoms, healthcare utilisation, demographics, medications, blood test results and lung function.

Chief Investigator – Andrew Menzies-Gow

Funder - Imperial College, London

Location of research – Imperial College / Royal Brompton Hospital, London

Date of approval – 7/1/11

Completion – October 2012

Reference - Obesity associated severe asthma represents a distinct clinical phenotype – Analysis of the British Thoracic Society Difficult Asthma Registry patient cohort according to body mass index. *Chest*. 2013 Feb 1;143(2):406-414

<https://pubmed.ncbi.nlm.nih.gov/23064546/>

Project (2)

Title – Determining sub-phenotypes of severe asthma - cluster analysis of registry patients

Chief Investigator – Professor Chris Brightling

Funder – Asthma UK

Location of research – University of Leicester / Glenfield Hospital Leicester

Date of approval – 20/10/10

Reference - Statistical Cluster Analysis of the British Thoracic Society Severe Refractory Asthma Registry: Clinical Outcomes and Phenotype Stability. *PLoS One*, July 24 2014.

<https://pubmed.ncbi.nlm.nih.gov/25058007/>

Project (3)

Title – Health economics of refractory asthma and steroid exposure – healthcare cost of refractory asthma and the prevalence and cost of steroid induced morbidities.

Chief Investigator – Professor Liam Heaney

Funder – GlaxoSmithKline and HoffmanLaRoche

Location of research – QUB / Belfast City Hospital

Date of approval – 1/4/11

Reference - Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. *Thorax*, May 11 2012. Published online

<http://thorax.bmj.com/content/early/2012/05/10/thoraxjnl-2012-201869>

Reference - The Cost of Treating Severe Refractory Asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. *Thorax*, June 10 2014. Published Online

<http://thorax.bmj.com/content/early/2014/06/10/thoraxjnl-2013-204114>

Reference - Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. *Thorax*. 2016 Apr;71(4):339-4 <http://thorax.bmj.com/content/71/4/339.long>

[The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis.](#)

Barry LE, Sweeney J, O'Neill C, Price D, Heaney LG. *Respir Res*. 2017 Jun 26;18(1):129

Project (4)

- Title – Influence of smoking status in severe asthma
- Chief Investigator – Professor Neil Thompson
- Funder
- Location of research –Gartnavel Hospital, Glasgow
- Date of approval -14/02/11
- Completed October 2012
- Reference -Clinical outcomes and inflammatory biomarkers in current smokers and ex-smokers with severe asthma. *JACI*, April 2013. Published online
<https://pubmed.ncbi.nlm.nih.gov/23419540/>

Project (5)

- Title – Refractory asthma in elderly patients in the UK
- Chief Investigator – Dr Rekha Chaudhuri
- Funder – Self funded
- Location of research –Gartnavel Hospital, Glasgow
- Date of approval – 15/12/12
- Reference - Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. *Respir Med.* 2016 Sep;118:46-52. doi: 10.1016/j.rmed.2016.07.005. Epub 2016 Jul 9
- <https://pubmed.ncbi.nlm.nih.gov/27578470/>

Project (6)

- Title – Efficacy of Bariatric Surgery in obese severe asthmatics in the UK
- Chief Investigator – Dr Rob Niven
- Funder – Self funded
- Location of research – Wythenshawe Hospital
- Date of approval – 25/06/13

Project (7)

- Title – Audit of the safety of Bronchial Thermoplasty using a national registry
- Chief Investigator – Professor Liam Heaney
- Funder – The National Institute for Health and Care Excellence (NICE)
- Location of research – Newcastle & York External Assessment Centre (EAC) for the NICE Technology Evaluation Programme
- Date of approval – January 2012
- Reference - Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. *J Asthma.* 2017 Oct;54(8):872-879
<https://pubmed.ncbi.nlm.nih.gov/27905828/>

Project (8)

- Title – Evidence for benefit of dedicated severe asthma services in the UK
- Chief Investigator – Dr Andrew Menzies-Gow
- Funder – Self funded
- Location of research – Royal Brompton Hospital London
- Date of approval – January 2015
- Dedicated severe asthma services improve health-care use and quality of life. *Chest.* 2015 Oct;148(4):870-876. doi: 10.1378/chest.14-3056.
<https://pubmed.ncbi.nlm.nih.gov/25789861/>

Project (9)

- Title – Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era
- Chief Investigator – Professor Liam Heaney
- Funder – Self funded
- Location of research – Queen’s University Belfast
- Date of approval – October 2019
- Manuscript under review with *Thorax 2020*

Project (10)

- Title – Risk factors for frequent exacerbations in a real-world severe asthma adult population
- Chief Investigator – Dr Rekha Chaudhuri
- Funder – Self funded
- Location of research – Gartnavel Hospital Glasgow
- Date of approval – October 2019
- Manuscript being submitted to *Journal of Allergy in Practice*

Project (11)

- Title – An exploration of severe asthma in ethnic minority groups within the UK
- Chief Investigator – Dr John Busby / Dr Paul Pfeffer
- Funder – Self funded
- Location of research – Queen’s University Belfast & St Barts Hospital London
- Date of approval – October 2019

Project (12)

ISAR

- Title – Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR)
- Chief Investigator – Prof David B Price – UK Leads – Liam Heaney, Andrew Menzies-Gow, Paul Pfeffer, David Jackson
- Funder – Optimum Patient Care Global Limited & AstraZeneca
- Location of research – International <http://isaregistries.org/isar-research-updates/>
- Date of approval – October 2017

Project (13)

SHARP

- Title – Characteristics and treatment regimens across ERS SHARP severe asthma registries
- Chief Investigator – Dr. Anke H. Maitland-van der Ze – UK Lead Liam Heaney
- Funder – European Respiratory Society & Sanofi, TEVA, Novartis, GSK, Chiesi
- Location of research – Europe-wide <https://sharp-crc.org>
- Date of approval – May 2020

Projects agreed at Steering Committee May 2020 (pending)

- a. Biologic use – biologic qualification overlap, outcomes and characteristics of biologic
- b. switching in Registry?
- c. What is the economic burden of severe asthma – pre-biologic and post-biologic?
- d. Features of severe asthma patients with FEV1 <40%?
- e. Obese versus non-obese severe asthma – what are differences?
- f. Proportion of UKSAR who would qualify for biologic clinical trials? – outcomes in
- g. those who would NOT have qualified for a clinical trial?
- h. EuroQoL v ACQ outcome post biologic therapy – does EuroQoL move in “super-responders”?